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RESUMO – Introdução: A eficácia e segurança da radiação UVB no tratamento da psoríase infantil e da adolescência encontra-se 
bem descrita na literatura. Contudo, existem poucos dados no que concerne à utilização de psoraleno e UVA (PUVA) nesta faixa 
etária. O objectivo do presente trabalho é avaliar a eficácia e segurança a curto prazo da terapêutica com PUVA numa população 
de adolescentes com psoríase. Métodos: Revisão e análise retrospectiva dos dados clínicos relativos aos doentes com psoríase com 
idade entre 13 e 17 anos. A população analisada incluiu 20 doentes, dezoito com psoríase em placas moderada a grave e dois 
com psoríase gutata. Resultados: Nove doentes foram tratados com apenas um ciclo de PUVA, e os restantes com dois. Foram 
associadas terapêuticas sistémicas em 52%. A taxa de resposta total foi de 86,2%, com uma média global de 16,7 tratamentos 
de PUVA e uma dose cumulativa total média de 174,0 J/cm2. O tempo até recidiva foi de 4,3 meses, e em 2 doentes (10%) não 
houve recidiva durante um ano de seguimento. Observaram-se efeitos secundários em 3 doentes (15%), nomeadamente náuseas 
e eritema cutâneo. Conclusões: A fotoquimioterapia demonstrou boa eficácia na nossa população de adolescentes. Os efeitos 
secundários foram reduzidos e não motivaram suspensão da terapêutica. O potencial carcinogénico da radiação UVA poderá ser 
uma limitação importante desta modalidade terapêutica, pelo que são necessários mais estudos que avaliem a sua segurança a 
longo prazo.
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Systemic Photochemotherapy in the Treatment of 
Adolescent Psoriasis 
ABSTRACT – Introduction: Ultraviolet-B radiation is known to be effective and safe in childhood and adolescent psoriasis, but little 
has been published on the combined use of psoralen with ultraviolet-A radiation. The aim of this work is to assess the efficacy and 
short-term safety of systemic photochemotherapy in an adolescent population. Methods: Relevant clinical data on psoriatic patients 
aged 13 to 17 was retrospectively collected and analyzed. The sample population included twenty patients, eighteen with moderate 
to severe plaque-type psoriasis and two with guttate psoriasis. Results: Nine patients were treated with one single cycle and the 
remaining eleven with two cycles, in association with systemic therapies in 52%. Total improvement rate was 86.2%, with an ave-
rage of 16.7 treatments per patient and a mean total cumulative dose of 174.0 J/cm2. The mean time for disease relapse was 4.3 
months and two patients (10%) did not experience relapse during one-year follow-up. Side effects occurred in three patients (15%), 
namely nausea and erythema. Conclusions: Photochemotherapy showed to be highly effective in our adolescent population. Side 
effects were minor and none led to therapy discontinuation. Carcinogenic potential of ultraviolet-A radiation might be an important 
limitation. Further studies are warranted to access long-term safety of photochemotherapy.
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INTRODUCTION
Psoriasis is a chronic burdensome skin condition com-
monly affecting under 18-years-old individuals.1 Facial invol-
vement and pruritus occur more frequently in this age group.2 
Extensive childhood and adolescent psoriasis treatment is 
often challenging due to disease’s potential impact in psycho-
logical development and the need to avoid systemic agents’ 
toxicity.3 Treatment efficacy and potential side effects have to be 
considered when selecting therapeutic modality in this context.
Several phototherapeutic options are available, such as 
narrowband UVB (nb-UVB), broadband UVB (bb-UVB), syste-
mic and topic psoralen-UVA photochemotherapy (PUVA and 
topic PUVA, respectively) or excimer laser therapy. Treatment 
is selected on a case-to-case basis according to diagnosis, 
disease severity, skin phototype and age.4 
UVA with longer wavelengths penetrate deeper into the 
skin and are recommended for the treatment of very thick pso-
riatic plaques.4,5 In adults, PUVA therapy is known to be more 
effective than nb-UVB, with reported efficacy rates of 80% vs 
70%.5 Treatment protocol includes 2 to 3 weekly sessions, star-
ting at 75% of the minimal phototoxic dose (MPD) for UVA or 
according to skin phototype. Between one to two hours befo-
re radiation exposure, 8-methoxypsoralen (8-MOP) dosed at 
0.5-0.6 mg/kg is administered orally. The radiation dose is 
increased by 10 to 20% in each session if no erythema occurs, 
until a maximum of 6 J/cm2 per treatment.6  
PUVA is not routinely used in patients younger than 12 
years due to its carcinogenic potential, well-known side effects 
(e.g. nausea, vomiting, ocular toxicity, headaches, phototoxici-
ty, hepatotoxicity) and the need of sun protection measures in 
the 24 hours after 8-MOP ingestion.4 Recent evidence-based 
recommendations have concluded that there is no increased 
risk of PUVA-associated cataract provided that ocular protec-
tion measures are followed.5
Available evidence supports nb-UVB effectiveness and sa-
fety to treat childhood psoriasis. Eleven studies7-17 enrolling 
295 children reported efficacy rates of 60-92.9%, without se-
vere short-term side effects. 
Nonetheless, little has been published on the use of sys-
temic PUVA in under 18-years-old patients. To the best of our 
knowledge, only one series including seven adolescents (ave-
rage age of 15 ± 0.7 years) has been published.10 Three pa-
tients had guttate psoriasis, three plaque-type psoriasis and 
one had both. A response rate of 83.3% was achieved at an 
average of 28 treatments and a total dose of 498.8 ± 377.0 
J/cm2. More recently, de Jager and co-workers18 reviewed 
three cases of children treated with systemic PUVA. One pa-
tient with plaque-type psoriasis had a complete response after 
18 PUVA treatments.19 The other two, with erythema annula-
re centrifugum-type psoriasis cleared with 15 and 21 treat-
ments.20 No severe side effects were observed. 
Little data is available regarding the use of topical PUVA 
to treat childhood psoriasis. In younger children, the absen-
ce of systemic side effects and the shorter duration of photo-
sensitization favor the use of this PUVA modality, 15 however 
topical PUVA is time consuming and less convenient4; thus 
other treatment options are generally preferred. To date, only 
one case of childhood psoriasis treated with topical PUVA has 
been reported.18
The aim of this observational retrospective study is to as-
sess PUVA efficacy and short-term safety in the treatment of 
moderate to severe psoriasis in an adolescent population. 
METHODS
Psoriatic patients aged 12 to 17 who had been treated 
with systemic photochemotherapy in our department over a 
17-year-period (January 1997 to December 2013) were in-
cluded. Data was retrospectively collected from phototherapy 
charts and clinical records.  Patients who had previously recei-
ved phototherapy of any kind were excluded.
Treatment was administered twice weekly on non-conse-
cutive days, according to a standardized protocol, using a 
Waldmann UV8001K cubicle with 27 UVA and 13 UVB fluo-
rescent lamps (Waldmann Lichttechnik Gmbtt, Schwenningen, 
Germany):
•	 Oral	8-MOP	was	given	at	0.6	mg/kg	120	minutes	prior	to	
UVA exposure. 
•	 The	initial	radiation	dose	was	1.5	and	2	J/cm2,	respective-
ly for phototype II and III.
•	 Dose	was	subsequently	increased	by	0.5	J/cm2,	to	a	ma-
ximum dose of 5 J/cm2. 
•	 Incremental	increases	were	decided	every	session	depen-
ding on the presence or absence of erythema and pigmen-
tary response. MPD was not calculated routinely. 
•	 Face	and	genitals	were	protected	during	treatment	unless	
there were significant lesions on those areas. 
•	 All	 patients	 wore	UV	 protection	 sunglasses	 during	 treat-
ment and in the following 24 hours whenever outdoors. 
•	 Ophthalmology	consultation	was	not	routinely	recommen-
ded.
Studied variables included age, gender, phototype, type of 
psoriasis, time since diagnosis, family history of psoriasis, co-
-morbidities, initial Psoriasis Area Severity Index (PASI), num-
ber of phototherapy cycles, number of sessions and dose per 
cycle, cumulative dose, adverse events, final PASI and time to 
relapse.
Main clinical outcome was PASI score decrease. Patients 
who improved >75%, between 50 and 75%, and less than 
50% of initial PASI score were considered good, moderate and 
non-responders to treatment, respectively. 
Statistical analysis was performed with Excel and RStudio 
using Chi-squared test, Fisher’s exact test and Kruskal-Wallis 
test. Statistical significance was defined as p < 0.05.
RESULTS
Twenty patients were included. Table 1 outlines their cha-
racterization according to demographic and clinical variables.
Overall, the 20 patients included underwent 29 PUVA 
cycles, as summarized in Table 2.
Overall, the average number of treatments per patient was 
16.7 and the mean total cumulative dose was 174.0 J/cm2. In 
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25 out of 29 PUVA cycles (86.2%), an improvement of at least 
75% of initial PASI score was observed. One patient failed to 
achieve a 50% PASI improvement despite 19 treatments (total 
cycle dose 81.5 J/cm2). The remaining three patients withdrew 
the treatment after a mean of 4.3 PUVA sessions, all for non-
-clinical reasons. Side effects occurred in three cases (15%), 
namely nausea in two of them and erythema in one patient. 
None led to interruption or discontinuation of treatment.
The mean disease relapse time was 4.3 months, varying 
from 1 to 9 months. Two patients did not experience relapse 
during one-year follow-up after one single PUVA cycle (dose 
89 and 174 J/cm2, respectively). One of them had been diag-
nosed one year before with guttate-type psoriasis and the 
other had 2-year evolving plaque-type psoriasis.
Systemic therapies were associated during 15 out of 29 
PUVA cycles (52%). When comparing these 15 cycles with 
those 14 PUVA courses without concomitant systemic medica-
tions, a higher average number of treatments per cycle (19.9 
vs 12.8) and a higher mean dose (107.9 vs 93.6 J/cm2) were 
needed to clear patients with an associated systemic medica-
tion and the rate of improvement was lower (80% vs 85.7%,). 
Those differences were not statistically significant.
The need for those therapies was correlated with higher 
disease severity and higher number of treatments (p = 0.022) 
on the first cycle and, on the second cycle, there was also a 
positive association with male gender (p = 0.025) and family 
history of psoriasis (p=0.024). Conversely, significantly fewer 
systemic therapies were prescribed to patients with guttate 
psoriasis (p = 0.016). 
No significant correlation between age, phototype, dura-
tion of the disease or previous systemic therapies and radiation 
dose, duration of treatment or time to relapse was identified.
DISCUSSION
According to our data, photochemotherapy is a highly 
effective therapeutic approach for moderate to severe cases of 
adolescent psoriasis. We observed an overall improvement rate 
of 86.2%. A similar efficacy rate (83.3%) was reported in the 
only published series of PUVA-treated psoriatic adolescents10, 
although a higher average number of treatments (28±22.8 vs 
16.7±7.5 treatments, respectively), as well as a higher total 
cumulative dose (498.8±377 vs 174±142.5 J/cm2) were 
Table 1 - Characterization of the 20 patients 
treated with PUVA
Gender
Female: 15 (75%)
Male: 5 (25%)
Age in years (mean ± 
SD; range)
15.7±1.4; 13-17
Skin phototype
II: 7 (35%)
III: 13 (65%)
Psoriasis type
Plaque: 16 (80%) *
Guttate: 4 (20%) **
Time since diagnosis 
(mean, years)
5 ± 4.1
Previous therapies
Topical corticosteroids:  
20 (100%)
Systemic retinoids: 10 
(50%)
Cyclosporine A: 1 (5%)
PASI score (mean) 15.7 ± 3.2
Number of PUVA cycles
One: 11 patients (55%) 
2 males and 9 females
Two: 9 patients (45%)
3 males and 6 females
Number of phototherapy 
cycles (including nb and 
bb UVB) (mean)
1.9 ±1.1
*one patient had also concomitant palmoplantar involvement; ** none had 
personal history of upper respiratory streptococcal infection; SD, standard 
deviation
Table 2 - Relevant information on PUVA therapy performed over the studied period 
Number of 
treatments 
(mean, SD)
Dose in J/cm2 
(mean, SD)
Duration 
in months 
(mean, SD)
PASI 75 
improvement
(n; %)
Non
responders
(n)
Withdrawal
(n; %)
Associated 
systemic 
therapies
Time to 
relapse 
in months 
(mean, SD)
First cycle
(n = 20)
17.2 ± 5.8
111.0 ± 
60.9
2.9 ± 1.3 18; 90% 1 1; 5%
10 (50%) 
retinoid*;
1 (5%) CyA**
3.6 ± 3.0***
Second cycle
(n = 9)
15.6 ± 10.6
123.6 ± 
118.6
2.8 ± 2.5 7; 77.8% 0 2; 22.2% 
4 (44%) 
retinoid*
7.5 ± 4.9***
Total
(29 cycles)
16.7 ± 7.5
Total 
cumulative 
dose: 174.0 
± 142.5
2.9 ± 2.5 25; 86.2% 1 3; 10.4% 15 (52%) 4.3 ± 3.6***
* Acitretin was prescribed to 2 male patients on the first cycle; the remaining retinoids correspond to isotretinoin;** CyA was being tapered with fast relapse when the patient 
was proposed to phototherapy, with overlap of both therapies in a short period; *** no available follow-up information for 7 patients on the first cycle and 5 on the second; 
SD, standard deviation
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reported10. Nevertheless in the previously published series no 
systemic therapies were associated with PUVA, as was the case 
for some of our patients. 
Published series of nb-UVB-treated psoriatic children re-
ported an average of 19-25.8 treatments per cycle, which is 
also higher than our numbers. The response rates on those se-
ries ranged between 65-92.9%.10,15 On the other hand, Archier 
and co-workers21 concluded on a recent systematic review that 
PUVA seems to clear adult psoriasis more reliably and with 
fewer sessions than UVB treatment. In childhood, available 
data seems to point towards a similar conclusion; however, 
further investigation is needed to confirm this hypothesis.
The response rate to PUVA therapy in the present study was 
similar or even higher than that reported for other systemic 
treatments (80-91.7% to metothrexate18 and 68% to etaner-
cept).22 Advantages of PUVA are the lack of the systemic im-
munosuppression associated with systemic treatments and the 
favorable safety profile. In our patients, only minor side effects 
occurred, none of which leading to therapeutic discontinuation.
Time to relapse was relatively short in our patients when 
compared to that reported for nb-UVB7 (4.3 vs 20 months). It 
is worth highlighting that two adolescents had no relapse of 
the disease within one-year follow-up and were not conside-
red when calculating mean time to relapse. Furthermore, five 
of the remaining 18 patients (27.8%) are currently being trea-
ted with biologic agents, hence reflecting the persistence and 
severity of their disease, which might explain the short time to 
relapseobserved in our study.
Systemic therapies were associated in about half of the 
performed PUVA cycles. Those patients were treated with oral 
medications as first line systemic therapy but did not achieve 
a satisfactory clinical response. Photochemotherapy was then 
started and ongoing medications were maintained due to di-
sease severity, being reduced as clinical response with the com-
bined approach was achieved. The potential harm caused by 
associating systemic therapies may be counterbalanced by 
lower time under those medications and lower administered ra-
diation dose, with a favorable risk-benefit relationship usually 
reported. Nevertheless, the higher severity of patients with asso-
ciated systemic therapies that were included in our study could 
not show the advantage of a reduced exposure to UVA. 
Actually, these associated therapies tend to be used in 
cases of more severe disease and potentially requiring a hi-
gher number of treatments per cycle, therefore justifying its 
use. Likewise, patients who needed an associated systemic 
therapy on the second PUVA cycle were more likely to be male 
and have positive family history of the disease. These features 
have also been linked to psoriasis severity.23,24 thus explaining 
the need of a more intensive treatment approach. 
The potentially associated carcinogenic risk is another 
concern of using phototherapy to treat young patients, parti-
cularly if considering the clear dose-effect relationship25 and 
the long-life expectancy of this group. Moreover, psoriasis is a 
chronic disease and most patients will be likely to require other 
treatments in their lifetime. For this reason, a high radiation 
dose in young patients should be avoided as it might limit 
future therapeutic approaches. Treatment with more than 200 
PUVA sessions or with over 2000 J/cm2 has been reported to 
significantly increase carcinogenic risk in adulthood.25 Never-
theless, these numbers are significantly higher than those of 
our case studies. 
Additionally, association of systemic retinoids to PUVA the-
rapy is known to lower carcinogenic risk,5 and these drugs 
were prescribed to about half of the patients in our study. 
However, retinoids cannot prevent nevi stimulation induced by 
radiation, which is also a concern for young patients. 
Although retrospective design, sample size and the lack 
of assessment for long-term oncogenic risk are limitations of 
our study, this is currently the largest series of data on under 
18-years-old psoriatic patients treated with PUVA. Concomi-
tant systemic therapies, used in more severe cases, also limit 
the assessment of PUVA efficacy alone. 
CONCLUSIONS
In view of the reported effectiveness and short-term safety 
of photochemotherapy in our adolescent population, it may 
be a valid therapeutic approach in cases of extensive disea-
se, thick plaques or refractivity to other therapeutic modalities. 
Nonetheless, the withdrawal rate (10.4%, all cases for reasons 
other than clinical) and school absenteeism might limit the use 
of this therapeutic option in this group.
Further studies are warranted to confirm PUVA efficacy 
and short-time safety in children and adolescents with psoria-
sis, as monotherapy or in combination with other systemic me-
dications, as well as to access its long-term safety concerning 
skin cancer and nevi stimulation.
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